TW202228693A - 用於治療癌症之組合療法 - Google Patents

用於治療癌症之組合療法 Download PDF

Info

Publication number
TW202228693A
TW202228693A TW110137116A TW110137116A TW202228693A TW 202228693 A TW202228693 A TW 202228693A TW 110137116 A TW110137116 A TW 110137116A TW 110137116 A TW110137116 A TW 110137116A TW 202228693 A TW202228693 A TW 202228693A
Authority
TW
Taiwan
Prior art keywords
cancer
azd5305
pharmaceutically acceptable
acceptable salt
carboplatin
Prior art date
Application number
TW110137116A
Other languages
English (en)
Chinese (zh)
Inventor
伊麗莎貝塔 里奧
Original Assignee
瑞典商阿斯特捷利康公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW202228693A publication Critical patent/TW202228693A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110137116A 2020-10-08 2021-10-06 用於治療癌症之組合療法 TW202228693A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089195P 2020-10-08 2020-10-08
US63/089,195 2020-10-08

Publications (1)

Publication Number Publication Date
TW202228693A true TW202228693A (zh) 2022-08-01

Family

ID=78293953

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110137116A TW202228693A (zh) 2020-10-08 2021-10-06 用於治療癌症之組合療法

Country Status (19)

Country Link
US (1) US20230372333A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225297B1 (cg-RX-API-DMAC7.html)
JP (1) JP7818585B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230083291A (cg-RX-API-DMAC7.html)
CN (1) CN116194110B (cg-RX-API-DMAC7.html)
AU (1) AU2021356123B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023005160A2 (cg-RX-API-DMAC7.html)
CA (1) CA3197056A1 (cg-RX-API-DMAC7.html)
DK (1) DK4225297T3 (cg-RX-API-DMAC7.html)
ES (1) ES3005507T3 (cg-RX-API-DMAC7.html)
FI (1) FI4225297T3 (cg-RX-API-DMAC7.html)
HU (1) HUE069249T2 (cg-RX-API-DMAC7.html)
IL (1) IL301687A (cg-RX-API-DMAC7.html)
MX (1) MX2023004156A (cg-RX-API-DMAC7.html)
PL (1) PL4225297T3 (cg-RX-API-DMAC7.html)
PT (1) PT4225297T (cg-RX-API-DMAC7.html)
TW (1) TW202228693A (cg-RX-API-DMAC7.html)
WO (1) WO2022074124A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304965B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
US20230250428A1 (en) * 2022-02-07 2023-08-10 Alliance Of Cardiovascular Researchers Method and composition for early detection of malignancies
IL316019A (en) * 2022-04-07 2024-11-01 Astrazeneca Ab Combined treatment for cancer
CA3254948A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Polytherapy for the treatment of cancer
CN121464135A (zh) * 2023-07-07 2026-02-03 优领医药科技(香港)有限公司 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物

Also Published As

Publication number Publication date
HUE069249T2 (hu) 2025-02-28
ES3005507T3 (en) 2025-03-14
DK4225297T3 (da) 2025-01-02
KR20230083291A (ko) 2023-06-09
PT4225297T (pt) 2024-12-30
EP4225297A1 (en) 2023-08-16
JP2023546362A (ja) 2023-11-02
FI4225297T3 (fi) 2024-12-10
US20230372333A1 (en) 2023-11-23
WO2022074124A1 (en) 2022-04-14
AU2021356123B2 (en) 2025-01-09
CA3197056A1 (en) 2022-04-14
EP4225297B1 (en) 2024-10-23
ZA202304965B (en) 2024-09-25
CN116194110B (zh) 2025-06-17
PL4225297T3 (pl) 2025-03-17
CN116194110A (zh) 2023-05-30
MX2023004156A (es) 2023-05-03
IL301687A (en) 2023-05-01
AU2021356123A1 (en) 2023-06-08
BR112023005160A2 (pt) 2023-04-18
JP7818585B2 (ja) 2026-02-20

Similar Documents

Publication Publication Date Title
AU2021356123B2 (en) Combination therapy for treating cancer
EP4631942A1 (en) Pan-kras degrading agent, and preparation method therefor and use thereof
EP3658148B1 (en) Macrocyclic compounds and uses thereof
US11666574B2 (en) Combination therapy involving diaryl macrocyclic compounds
KR20210018291A (ko) 항암 핵 호르몬 수용체-표적화 화합물
KR20210005222A (ko) Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
CN107949557B (zh) 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类
UA122221C2 (uk) 4Н-ПІРОЛО[3,2-c]ПІРИДИН-4-ОНОВІ ПОХІДНІ
CN117580839A (zh) 抗癌核激素受体靶向化合物
JP2023545096A (ja) 抗体-薬物コンジュゲート及びparp1選択的阻害薬の組み合わせ
EP4058464A1 (en) Anti-cancer nuclear hormone receptor-targeting compounds
JP2011144182A (ja) 2,5−ジオン−3−(1−メチル−1h−インドール−3−イル)−4−[1−(ピリジン−2−イルメチル)ピペリジン−4−イル]−1h−インドール−3−イル]−1h−ピロール一塩酸塩の結晶
JP2018521095A (ja) 変異イソクエン酸デヒドロゲナーゼidh1 r132hの阻害剤
KR20240127394A (ko) 뇌 종양 및 신경모세포종의 치료 방법
US20250367205A1 (en) Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
CN103534250B (zh) 用于治疗免疫障碍的被取代的吲哚衍生物
EP3233839B1 (en) Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors
HK40099137B (en) Combination therapy for treating cancer
HK40099137A (en) Combination therapy for treating cancer
EA049465B1 (ru) Комбинированная терапия для лечения рака
CN120904168A (zh) 第四代egfr抑制剂、及其制备方法和在药学上的应用
TW202523322A (zh) 吉西他濱抗癌衍生物及其抗癌醫藥用途和製備方法
KR20150079665A (ko) 치환된 인돌 유도체
BR122024006404A2 (pt) Compostos inibidores de tirosina e de cdc2 específica de treonina cinase e composição farmacêutica compreendendo os mesmos